{"filing":{"accession_number":"0001193125-26-347897","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"kpti-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-20260813.htm"},"events":[{"id":27512,"run_id":25082,"accession_number":"0001193125-26-347897","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 disclosing financial results including total revenue of $33.4 million, net product revenue of $30.8 million, and net loss of $67.0 million. The filing explicitly states the company \"announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The release also includes forward guidance for full-year 2026 revenue and expense ranges.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29088,"accession_number":"0001193125-26-347897","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including total revenue of $33.4 million, net product revenue of $30.8 million, and net loss of $67.0 million. The filing explicitly states the company \"announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The release also includes forward guidance for full-year 2026 revenue and expense ranges.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:38:37.934801+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29088,"accession_number":"0001193125-26-347897","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results including total revenue of $33.4 million, net product revenue of $30.8 million, and net loss of $67.0 million. The filing explicitly states the company \"announced its financial results for the quarter ended June 30, 2026\" with the full press release furnished as Exhibit 99.1, which is the standard format for Item 2.02 earnings disclosures. The release also includes forward guidance for full-year 2026 revenue and expense ranges.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:38:37.934801+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-08-13"}]}